Why Alvotech’s (ALVO) Stock Is Down 6.56%
As of Friday, August 21, Alvotech’s ALVO share price has dipped by 6.56%, which has investors questioning if this is right time to buy.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn’s disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
Commentary & Analysis
Why Alvotech’s (ALVO) Stock Is Down 5.06%
As of Monday, August 17, Alvotech’s ALVO share price has dipped by 5.06%, which has investors questioning if this is right time to buy.Jenna Brashear
Is Alvotech (ALVO) Overvalued?
We dive into why Alvotech (ALVO) could be considered overvalued on 2026-08-14, based on AAII’s Value Score and Grade.Michael Rose
Why Alvotech’s (ALVO) Stock Is Down 5.34%
As of Monday, August 03, Alvotech’s ALVO share price has dipped by 5.34%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Alvotech’s (ALVO) Stock Is Up 8.68%
As of Friday, July 31, Alvotech’s ALVO share price has surged by 8.68%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | ALVO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,581.1 | $292.6 | 50% |
|
| Shares Out (Mil) | 299.2 | 54.4 | 83% |
|
| Institutional Ownership | 95.8% | 93.2% | 68% |
|
| Float (Mil) | 140.8 | 40.2 | 68% |
|
| Beta | 0.18 | 0.94 | 12% |
|
| Avg Daily Volume (000s) | 934 | 544 | 69% |
|
| Price Change (52-week) |
(46.2%) | 59.7% | 15% |
|
| Growth | ALVO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 53.4% | 13.6% | 96% |
|
| Net Income (5yr) | 16.7% | (10.1%) | 67% |
|
| EPS (5yr) | 15.5% | 16.0% | 58 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 25.4% | (15.6%) | 83% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 4 | 4 | |
| Current EPS | $0.009 | ($0.008) | $0.209 | |
| Month Ago EPS | $0.018 | $0.027 | $0.235 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $0.000 | $0.021 | $0.179 | |
| Year/Year Chg | (104.0%) | (108.3%) | 370.8% | |
| Financials | ALVO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $495 | $37 | 41% |
|
| Net Income (TTM) (Mil) | ($180) | ($43) | 7% |
|
| EPS (TTM) | ($0.608) | ($1.400) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($199) | ($31) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $213 | $2 | 85% |
|
| Long-Term Debt (Q1) (Mil) | $1,398 | $4 | 70% |
|
| Enterprise Value (Q1) (Mil) | $2,833 | $164 | 53% |
|
| Valuation | ALVO | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.83 | na |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ALVO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 60.7% | 64.2% | 73% |
|
| Net Margin | (36.3%) | (75.9%) | 14% |
|
| ROA | (12.7%) | (47.5%) | 24% |
|
| ROE | 72.7% | (55.0%) | 95% |
|
| Liabilities to Assets | 112.1% | 29.6% | 96% |
|
| F-Score | 4 | 3 | 33% |
|
Alvotech did not pass any screens on 8/21/2026.
